ABCL vs XERS Stock Comparison
XERS currently leads ABCL in this stock comparison, with AIQ scores of 78 vs 64. The clearest difference is value.
What is the main difference between ABCL and XERS?
XERS leads the current stock comparison as Xeris Biopharma Holdings, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
AbCellera Biologics Inc. vs Xeris Biopharma Holdings, Inc.
XERS leads
XERS leads by 14 AIQ points, primarily on Value and Risk Resilience. Wall Street currently favors ABCL on target upside.
Stable: 5 of 6 evidence groups support XERS, and its current signal state is conflicted.
AbCellera Biologics Inc.
Xeris Biopharma Holdings, Inc.
The Algovestiq AIQ Score currently favors XERS over ABCL, 78 versus 64 as of Nov 15, 2026. XERS's advantage is driven primarily by stronger value and risk resilience. XERS also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors ABCL. 5 of 6 covered evidence groups favor XERS today, and the comparison is rated Stable on stability: the leader is throwing conflicting signals. XERS lead: Stable — the AIQ differential has held near 14 points over 30 sessions. XERS leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.
Compare AbCellera Biologics Inc. and Xeris Biopharma Holdings, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare ABCL and XERS against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value47 vs 68XERS +21
- Risk Resilience34 vs 55XERS +21
- Quality61 vs 71XERS +10
- Momentum89 vs 98XERS +9
5 of 6 evidence groups favor XERS. XERS’s edge is concentrated in value and risk resilience.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum +2
No signal started or stopped since the prior session; its 4 active signals are unchanged.
Largest factor move: Value +1
No signal started or stopped since the prior session; its 9 active signals are unchanged.
XERS's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — ABCL and XERS both carry a full feed there.
The central trade-off
XERS (Xeris Biopharma Holdings, Inc.): the stronger current systematic profile, led by value and risk resilience.
ABCL (AbCellera Biologics Inc.): the counter-case, on analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
XERSXERS on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
ABCLABCL on combined revenue and EPS growth.
Value
XERSXERS on the peer-relative Value factor, by 21 points.
Momentum
XERSXERS on the Momentum factor, by 9 points.
Lower downside
XERSXERS on Risk Resilience, by 21 points.
Analyst upside
ABCLABCL on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors XERS, analyst targets favor ABCL. That disagreement is the most useful thing on this page.
| Measure | ABCL | XERS | Note |
|---|---|---|---|
| Implied upside to target | +50.9% | -10% | ABCL has more room |
| Target dispersion | +46.2% | +13.3% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 13 | 7 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
5 of 6 covered evidence groups favor XERS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | XERS | 64 vs 78 |
| Fundamentals | XERSon balance | revenue growth 162.7% vs 16.4%; EPS growth 27.8% vs 133.3%; TTM ROE -3.8% vs 23.1%; gross margin 75.6% vs 84.4%; operating margin -298% vs 12.7% — XERS takes 4 of 5 decided legs, not all of them |
| Valuation | XERS | Value 47 vs 68 |
| Technicals | XERS | Price vs 50-day -6.9% vs 60.1%; vs 200-day 58.8% vs 112.8% |
| Risk Resilience | XERS | Risk Resilience 34 vs 55 |
| Analyst expectations | ABCL | Target upside 50.9% vs -10% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ABCL and XERS and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 14 points. (supports the conclusion holding)
- 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on XERS.
How the comparison changed
120 daily snapshots · May 27 – Nov 13XERS lead: Stable — the AIQ differential has held near 14 points over 30 sessions.
- Today
- XERS +14
- 64 vs 78
- 7 sessions ago
- XERS +15
- 62 vs 77
- 30 sessions ago
- XERS +14
- 62 vs 76
- 90 sessions ago
- XERS +7
- 64 vs 71
The lead changed hands once in this window, most recently on Jun 9 when XERS moved ahead of ABCL.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 2 bearish / 1 neutral, conflicted
Only ABCL
- Beta Spike Warning — bearish, risk_regime, long horizon
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
6 bullish / 1 bearish / 2 neutral, conflicted
Only XERS
- 52-Week High Proximity — bullish, risk_regime, long horizon (0.7%)
- ADX Trend Strengthening — neutral, trend, medium horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
- RSI Overbought — bearish, momentum, short horizon
- TRIX Bullish Signal — bullish, momentum, short horizon
- Uptrend Structure Active — bullish, trend, long horizon
Both carry 2 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode.
XERS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -1.12%, AIQ +1 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.06%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1ABCL closes the Value gap — currently 21 points behind, the largest single contributor to XERS's edge.
- 2ABCL's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
- 3XERS's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
XERS leads on balance| Metric | ABCL | XERS |
|---|---|---|
| Revenue growth (YoY) | 162.7% | 16.4% |
| EPS growth (YoY) | 27.8% | 133.3% |
| Gross margin | 75.6% | 84.4% |
| Operating margin | -298% | 12.7% |
| Return on equity (TTM) | -3.8% | 23.1% |
| Debt to equity | 0.13 | 4.63 |
Performance
Split across windows| Metric | ABCL | XERS |
|---|---|---|
| 1 week (5 sessions) | -3.3% | 9.6% |
| 1 month (20 sessions) | -2.6% | 61.6% |
| 3 months (63 sessions) | 2.6% | 95.5% |
| 6 months (126 sessions) | 180.9% | 167% |
| Year to date | 236% | 112.2% |
| 1 year (252 sessions) | 189.4% | 119.5% |
Technicals
XERS has the stronger structure| Metric | ABCL | XERS |
|---|---|---|
| RSI (14) | 45.2 | 85.4 |
| ADX (14) | 11.9 | 47 |
| Price vs 50-day | -6.9% | 60.1% |
| Price vs 200-day | 58.8% | 112.8% |
| Volatility (1M, annualized) | 88.8% | 110.3% |
Risk
XERS is the more resilient| Metric | ABCL | XERS |
|---|---|---|
| Beta | 2.42 | 0.07 |
| Sharpe ratio | 1.73 | 1.67 |
| Sortino ratio | 3.02 | 2.99 |
| Max drawdown | -40.1% | -34.9% |
| Current drawdown | -22.5% | 0% |
| Annualized volatility | 85.3% | 57% |
| Value at risk (95%) | -7.1% | -4.3% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, ABCL or XERS?
On the Algovestiq AIQ Score, XERS is the stronger of the two as of Nov 15, 2026, scoring 78 against ABCL's 64. The edge comes from value and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is ABCL or XERS the better buy right now?
XERS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 5 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor XERS over ABCL?
The composite weights Quality, Value, Momentum and Risk Resilience. XERS leads Value by 21 points; XERS leads Risk Resilience by 21 points; XERS leads Quality by 10 points. XERS leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by ABCL simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.
Which has more analyst upside, ABCL or XERS?
Analyst price targets imply +50.9% upside for ABCL and -10% for XERS, so the Street currently favors ABCL. That points the opposite way to the AIQ Score, which favors XERS. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, ABCL or XERS?
XERS is the better-valued of the two on the peer-relative Value factor. XERS on the peer-relative Value factor, by 21 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, ABCL or XERS?
ABCL on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, ABCL or XERS?
XERS on the Momentum factor, by 9 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, ABCL or XERS?
XERS is the more resilient of the two, so the other name carries the higher downside risk. XERS on Risk Resilience, by 21 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is ABCL more profitable than XERS?
XERS leads on the comparable margin measures — gross margin 75.6% vs 84.4%; operating margin -298% vs 12.7%; ttm roe -3.8% vs 23.1%.
Is XERS's lead over ABCL getting stronger or weaker?
XERS lead: Stable — the AIQ differential has held near 14 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-06-09, when XERS moved ahead of ABCL.
What would change the ABCL vs XERS verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ABCL closes the Value gap — currently 21 points behind, the largest single contributor to XERS's edge; ABCL's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; XERS's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about ABCL and XERS?
ABCL: 1 bullish / 2 bearish / 1 neutral, conflicted. XERS: 6 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ABCL is Golden Cross Active (bullish, long horizon). On XERS it is Golden Cross Active (bullish, long horizon).
Compare ABCL and XERS with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.